<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763659</url>
  </required_header>
  <id_info>
    <org_study_id>2032-06/07</org_study_id>
    <nct_id>NCT00763659</nct_id>
  </id_info>
  <brief_title>Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)</brief_title>
  <acronym>LUTEGA</acronym>
  <official_title>Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of LUTEGA is it to determine the long term effect (about 1 year) of the
      supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids on the
      optical density (OD) of macular pigment in patients with non- exudative age related
      maculopathy.

      Furthermore, it is to be examined whether changes of the optical density are different
      dosages dependent. Possible changes of lipofuscin content and effect on drusen in AMD
      patients are studied. The measurement of optical density of macular pigment uses the 1-
      wavelength reflection method recording reflection images at 460 nm by a fundus camera. The
      patients are investigated at baseline and are followed up over one year in four more visits.
      In addition to the OD- measurement each examination includes standardized visual acuity test
      (ETDRS), amsler- grid, slit lamp biomicroscopy, fundus photography (color and
      autofluorescence) and a blood sample.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optical density of macular pigment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Age Related Maculopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein/ Zeaxanthin + Omega-3-FA</intervention_name>
    <description>20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein/ Zeaxanthin + Omega-3-FA</intervention_name>
    <description>10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg Lutein, Zeaxanthin, Omega-3-FA</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All non- exudative forms of age related maculopathy

        Exclusion Criteria:

          -  Exudative age related maculopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¼rgen Strobel, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Dawczynski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, University Hospital</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Jens Dawczynski</investigator_full_name>
    <investigator_title>Prof. Dr. med. jens Dawczynski</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

